2019 年 36 巻 5 号 p. 591-593
Various clinical trials for peripheral neuropathy were published in 2018. Systematic PubMed search using terms, “neuropathy”, “peripheral neuropathy”, and “clinical trials” was performed with the time lock from January 1, 2018 through December 31, 2018. A total of 22 trials were found on diabetic neuropathy (DPN ; n=10), chemotherapy–induced peripheral neuropathy (CIPN ; n=7), hereditary ATTR amyloidosis (n=2), Guillain–Barre syndrome (GBS ; n=1), chronic inflammatory demyelinating polyneuropathy (CIDP ; n=1), and multifocal motor neuropathy (n=1). For painful DPN, exercise, pregabalin, alpha–lipoic acid, and spinal cord electric stimulation were effective for pain relief. For CIPN, exercise Calmangafodipir and Sigma–1 receptor ligand treatment showed possible beneficial effects. For ATTR amyloidosis, a tafimidis trial revealed a significantly beneficial effects on cardiomyopathy, and an anti–sense oligonucleotide, inotersen, showed improvedment in neuropathy and QOL scores. For immune–mediated neuropathies, clinical trials on eculizumab for GBS, subcutaneous immunoglobulin as a maintenance therapy for CIDP, and intravenous immunoblobulin as a maintenance therapy for multifocal motor neuropath were published. These results showed sustained research activity to develop new therapies for a number of peripheral nerve disorders.
